Esteve

esteve.png

Contact information

Esteve
Dr. Eduard Valentí, Director de Asuntos Regulatorios y Gerente de Calidad Farmacéutica
Av. Mare de Déu de Montserrat, 221
Barcelona
Barcelona
934466000
934504899
Areas of activity
  • A. Health Biotechnology
  • A. Health Biotechnology
  • Therapeutic areas
  • A. Health Biotechnology
  • Therapeutic areas
  • Analgesia & Pain
  • A. Health Biotechnology
  • Therapeutic areas
  • Genetic and rare diseases
  • A. Health Biotechnology
  • Therapeutic areas
  • Infectious diseases
  • A. Health Biotechnology
  • Therapeutic areas
  • Central nervous system
  • A. Health Biotechnology
  • Areas of activity
  • A. Health Biotechnology
  • Areas of activity
  • Biodrugs
  • A. Health Biotechnology
  • Areas of activity
  • Drug delivery
  • A. Health Biotechnology
  • Areas of activity
  • Screening
  • A. Health Biotechnology
  • Areas of activity
  • Gene Therapy
  • A. Health Biotechnology
  • Areas of activity
  • Vaccines
  • B. Agrifood Biotechnology
  • B. Agrifood Biotechnology
  • Agriculture / veterinary / environmental
  • B. Agrifood Biotechnology
  • Agriculture / veterinary / environmental
  • Animal health / Veterinary
  • C. Industrial Biotechnology
  • C. Industrial Biotechnology
  • APIs and green chemical
Commissions

Esteve is a private, fully integrated International Group that pursues innovation and excellence in the pharmaceutical-chemical industry, while maintaining its dedication to the promotion of health for the benefit of society.

Esteve invests significantly in R&D, focused in analgesia. Its lead program is a Sigma-1 receptor antagonist for neuropathic pain.

Products and services

Esteve is a diversified company marketing a wide range of ethical and OTC pharmaceutical products, vaccines, generics, products for veterinary use and it manufactures APIs. Esteve has also established strategic alliances, ISDIN for dermatological products and Esteve-Teijin-Healthcare in home respiratory therapy.

Areas of interest for future collaborations

Esteve is open to evaluating new opportunities for collaboration, especially in the area of analgesia.